Expertise in
26
conditions

Dr. Basem M. William

Ohiohealth Corporation
Columbus, OH
Expertise in
26
conditions
Specialties:Hematology Oncology | Hospital Medicine | Transplant Surgery
Accepting New Patients
Expertise in
26
conditions
OverviewInsuranceLocationsClinical Research

Overview

Basem William is a Hematologist Oncology specialist and a Hospital Medicine provider in Columbus, Ohio. Dr. William is highly rated in 26 conditions, according to our data. His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. William is currently accepting new patients.

His clinical research consists of co-authoring 75 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Transplant Surgery
Licenses
Hospitalist in ME
Hospital Affiliations
Grant Medical Center
Marion General Hospital
Riverside Methodist Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medical Health
  •  Humana

Locations

OHIOHEALTH CORPORATION
500 Thomas Ln, 2e, Columbus, OH 43214
614-566-9777

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug, Biological
Study Drugs: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2024
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2024
Intervention Type: Drug, Other
Study Drugs: Brentuximab Vedotin, Lenalidomide
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1/Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Withdrawn
Publish Date: December 09, 2021
Intervention Type: Drug
Study Drug: Avatrombopag
Study Phase: Phase 2
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2021
Intervention Type: Procedure, Drug
Study Drugs: Carmustine, Cytarabine, Etoposide, Melphalan, Venetoclax
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

76 Total Publications

Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Impact of chronic graft-versus-host disease on non-relapse mortality and survival.
Journal: Leukemia & lymphoma
Published: June 12, 2024
Similar Doctors
Expertise in
30
conditions
Dr. David A. Liebner
Hematology Oncology | Hematology | Oncology
Expertise in
30
conditions
Dr. David A. Liebner
Hematology Oncology | Hematology | Oncology

Osu Internal Medicine LLC

452 W 10th Ave, 
Columbus, OH 
 (2.8 mi)
614-293-3737
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Liebner is a Hematologist Oncology specialist and a Hematologist in Columbus, Ohio. Dr. Liebner is highly rated in 30 conditions, according to our data. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Myxoid Liposarcoma, and Synovial Sarcoma. Dr. Liebner is currently accepting new patients.

Marcos J. De Lima
Expertise in
21
conditions
Dr. Marcos J. De Lima
Hematology Oncology | Oncology | Hematology
Expertise in
21
conditions
Dr. Marcos J. De Lima
Hematology Oncology | Oncology | Hematology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
 (2.7 mi)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marcos De Lima is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. De Lima is highly rated in 21 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.

David P. Carbone
Expertise in
11
conditions
Dr. David P. Carbone
Hematology Oncology | Oncology
Expertise in
11
conditions
Dr. David P. Carbone
Hematology Oncology | Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (5.6 mi)
614-889-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Carbone is a Hematologist Oncology specialist and an Oncologist in Dublin, Ohio. Dr. Carbone is highly rated in 11 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Carbone is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile